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G protein-coupled receptors (GPCRs), the largest family of targets for approved drugs,
are rarely targeted for cancer treatment, except for certain endocrine and hormone-
responsive tumors. Limited knowledge regarding GPCR expression in cancer cells likely
has contributed to this lack of use of GPCR-targeted drugs as cancer therapeutics.
We thus undertook GPCRomic studies to define the expression of endoGPCRs
(which respond to endogenous molecules such as hormones, neurotransmitters and
metabolites) in multiple types of cancer cells. Using TaqMan qPCR arrays to quantify
the mRNA expression of ∼340 such GPCRs, we found that human chronic lymphocytic
leukemia (CLL) cells/stromal cells associated with CLL, breast cancer cell lines, colon
cancer cell lines, pancreatic ductal adenocarcinoma (PDAC) cells, cancer associated
fibroblasts (CAFs), and PDAC tumors express 50 to >100 GPCRs, including many
orphan GPCRs (which lack known physiologic agonists). Limited prior data exist
regarding the expression or function of most of the highly expressed GPCRs in these
cancer cells and tumors. Independent results from public cancer gene expression
databases confirm the expression of such GPCRs. We propose that highly expressed
GPCRs in cancer cells (for example, GPRC5A in PDAC and colon cancer cells and
GPR68 in PDAC CAFs) may contribute to the malignant phenotype, serve as biomarkers
and/or may be novel therapeutic targets for the treatment of cancer.
Keywords: breast cancer, cancer microenvironment, chronic lymphocytic leukemia, colon cancer, GPCR array,
orphan receptors, pancreatic cancer
Abbreviations: BMNK cell, Bone Marrow Natural Killer cell; CLL/B-CLL, Chronic Lymphocytic Leukemia/B-cell Chronic
Lymphocytic Leukemia; Ct/1Ct, Cycle threshold/Difference in Cycle threshold; EBI, European Bioinformatics Institute;
FPKMs, Fragments Per Kilobase of transcript per Million mapped reads; GPCR, G protein-coupled receptor; GtoPdb, Guide
to Pharmacology database; IUPHAR, International Union of Basic and Clinical Pharmacology; PDAC, Pancreatic Ductal
Adenocarcinoma; PDEC, Pancreatic Ductal Epithelial Cell; PSCs, Pancreatic stellate cells; RNA-seq, High throughput RNA
sequencing; TCGA, The Cancer Genome Atlas; TMM, trimmed mean of M values.
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INTRODUCTION
Knowledge regarding the biology of tumors and malignant
cells has greatly expanded in recent years. Several hallmarks of
cancer have been identified: proliferative signaling, replicative
immortality, evasion of growth suppressors, resistance to
cell death, induction of angiogenesis, and the activation of
invasion and metastasis (Hanahan and Weinberg, 2011). A key
recent focus for basic and clinical investigators has been the
identification of “driver mutations,” including ones that are
shared among anatomically distinct types of cancer and predicted
to be responsive to molecularly targeted therapeutics. In parallel
has been the growth of personalized (precision) medicine
approaches guided by genetic analyses that seek to identify such
driver mutations (Schwaederle et al., 2015; Borad and LoRusso,
2017; Chae et al., 2017; Hyman et al., 2017). In addition, increased
understanding of the immune suppression that contributes to
tumor growth and metastasis and development of therapeutics
directed at this immune suppression have yielded improved
clinical outcomes for a variety of cancers (Cogdill et al., 2017;
Gotwals et al., 2017; Lim and June, 2017).
In spite of such progress, new therapies are needed for
most cancers. In this regard, GPCRs, the largest family of
signaling receptors in humans and the largest family of protein
targets for approved drugs (Sriram and Insel, 2018), have
rarely been exploited as therapeutic targets in cancer with
the exception of certain endocrine cancers (e.g., pituitary,
adrenal, testes, ovarian) and hormone-responsive tumors
(e.g., breast and prostate cancer). Even though GPCRs are
not thought to be functionally mutated and commonly
expressed (i.e., they are not “genetic drivers”) in cancers,
GPCRs and post-GPCR signaling mechanisms play an
important role in regulating cellular functions integral to
the hallmarks of cancer (e.g., growth/proliferation, metabolism,
death/apoptosis, ion and nutrient transport, and migration;
Dorsam and Gutkind, 2007; Hanahan and Weinberg, 2011;
O’Hayre et al., 2014). GPCRs are not only expressed by
cancer cells themselves, but also by cell-types in the tumor
microenvironment, including stromal (fibroblast), vascular,
immune, and inflammatory cells. Numerous effects of GPCRs,
including their regulation of apoptotic cell death, are mediated by
the second messenger cAMP (Insel et al., 2012, 2014). Moreover,
as plasma membrane proteins, GPCRs should be targetable as
are numerous other types of cell surface proteins in various
cancers.
The lack of consideration of GPCRs as therapeutic targets
may relate, at least in part, to the limited information
regarding their expression by cancer cells and cells of the
tumor microenvironment. We therefore have used an unbiased
(GPCRomic) approach to identify and quantify GPCR expression
in cancer cells in order to identify GPCRs that may contribute to
the malignant phenotype and might be therapeutic targets. Here,
we present findings that utilize GPCR-specific PCR-based arrays,
RNA-seq, and mining of databases to define GPCR expression
of primary cancer cells, cancer cell lines, cells in tumor tissue,
and the tumor microenvironment. The findings reveal previously
unrecognized GPCR expression in these cells suggesting that they
could serve as novel biomarkers and therapeutic targets in various
types of cancer.
MATERIALS AND METHODS
Primary Cells and Cell Lines
Table 1 summarizes the cells used in the current studies and
the source from which they were obtained. Patient cells were
isolated after informed consent, under an Institutional Review
Board-approved protocol, and within the guidelines of the Health
Insurance Portability and Accountability Act. All cells were
grown under standard tissue culture conditions and studied when
growing at log phase and at low passage number.
Isolation of mRNA and Preparation of
cDNA
RNA was isolated using a Qiagen RNeasy MiniKit, with on-
column DNase-1 digestion (Qiagen, Valencia, CA, United States).
cDNA was synthesized using a Superscript III First Strand
Synthesis Kit (Invitrogen, Carlsbad, CA, United States) as per the
manufacturer’s instructions, using random hexamer priming.
Analysis of GPCR Expression
We used TaqMan GPCR arrays (Thermo Fisher Scientific) to
identify and quantify GPCR expression (Snead and Insel, 2012).
TABLE 1 | Human cells and cell lines used for assessment of GPCR expression.
Type of cancer Cells or cell lines
used
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The Taqman GPCR arrays for humans contain primers for
the majority (340) of GPCRs in peripheral tissues that have
endogenously expressed ligands (i.e., endoGPCRs), including
all well characterized GPCRs which are targets for approved
drugs (Sriram and Insel, 2018). mRNAs for only seven olfactory
receptors, one taste receptor, and three vision receptors are
detectable by these arrays. For each array, ∼1 µg of total RNA
converted to cDNA was loaded into a 384-well microfluidic
card along with TaqMan Universal PCR Master Mix according
to the manufacturer’s instructions. Exponential curves for each
detected cDNA were analyzed using RQ manager software. GPCR
expression was normalized to the Ct of 18S rRNA (whose Ct
was generally ∼12). Data are expressed as 1Ct = Ctx − Ct18S
for each GPCR (x) detected. We typically used a 1Ct of 25 as
the GPCR detection threshold, a value similar to that in prior
studies (Snead and Insel, 2012; Amisten et al., 2015; Walker
et al., 2015; Jung et al., 2016). Independent qPCR analyses
consistently confirmed the expression of array-identified GPCRs.
We also found excellent concordance between GPCR data from
TaqMan arrays and RNA-seq. We assigned G protein linkage of
GPCRs based on information for the primary or multiple linkages
in the IUPHAR/British Pharmacological Society (BPS) GtoPdb
(Alexander et al., 2017). Certain GPCRs reportedly have multiple
such linkages but this may depend on the cells studied and on
the use of transfection/over-expression approaches, which may
not accurately reflect signaling in cells in vivo. The patterns of
G protein linkages we report should therefore be considered
tentative. In figures that show the number of GPCR linkages (e.g.,
Figure 1), we include all reported linkages for a given GPCR.
Hence, the number of linkages indicated is generally greater than
the number of GPCRs identified. RNA-seq data on pancreatic
CAFs were generated as described in Wiley et al. (2018). In
brief, Truseq stranded mRNA libraries were sequenced at ∼25
million 75 bp single reads per sample, on an Illumina NextSeq
500 sequencer by DNA Link, Inc. (San Diego, CA, United States).
Data were analyzed via alignment using STAR (Dobin et al., 2013)
and quantification via Cuﬄinks (Trapnell et al., 2012) with the
hg38 reference genome and refseq annotations; and subsequently
via edgeR (Robinson et al., 2010) to facilitate comparison of gene
expression between samples. Accession number for RNA-seq
data: GSE101665.
Data Mining and Analysis
RNA-seq data for normal pancreas from the GTEx database
(GTEx Consortium, 2013) and pancreatic tumors from TCGA
(Weinstein et al., 2013) were downloaded from the Xena portal1
from data generated by the TOIL pipeline (Vivian et al., 2017).
Data were generated using alignment via STAR (Dobin et al.,
2013), and quantification via RSEM (Li and Dewey, 2011), using
the hg38 reference genome and Gencode V23 annotations2.
Gene-level RSEM estimated counts for normal pancreas (n = 165)
and pancreatic adenocarcinoma (PAAD, n = 179 tumors plus
four matched normal in TCGA) were downloaded, along with
information regarding phenotype. The histology of 147 of the
1xena.ucsc.edu
2https://xenabrowser.net/datapages/?hub=https://toil.xenahubs.net:443
179 tumors was consistent with PDAC; thus we compared the
expression data in those 147 tumors with that of normal pancreas.
The counts matrix with GTEx and TCGA samples was analyzed
via edgeR (Robinson et al., 2010) using TMM normalization to
obtain expression in counts per million (CPM). Exact testing
was used to evaluate differential expression. We used the batch
correction tool in Limma (Smyth, 2005) to verify that factors such
as plate identity, sequencing center or source collection center
(as relevant variables3) had minimal impact on GPCR expression.
GPCR expression was extracted by querying expression of genes
corresponding with annotated GPCR gene names from the
GtoPdb database (Alexander et al., 2017).
We determined GPCR expression in cancer cell lines from
the EBI database (Kapushesky et al., 2009) containing analyzed
samples via the iRAP pipeline4 (Fonseca et al., 2014), yielding
gene expression in FPKM, as computed by Cuﬄinks on aligned
BAM files generated using Tophat2 (Trapnell et al., 2012) with
GRCh37.66 from Ensembl as the reference human genome.
We set the detection threshold for GPCRs as >0.1 FPKM,
as used previously (Chettoor et al., 2014; Zhang et al., 2014),
which yields results comparable to the 1Ct = 25 threshold of
the TaqMan array data. GPRC5A expression in PDAC cell lines
assayed via RNA-seq was normalized to β-actin (ACTB) for
comparison with TaqMan array data and to facilitate comparison
of our GPRC5A expression data in control PDECs with the EBI
data for PDAC cell lines. Use of other housekeeping genes (e.g.,
GAPDH, β2 microglobulin) did not alter our conclusions.
Immunocytochemistry for Detection of
GPRC5A
BXPC-3 and MIA PaCa-2 cells (pancreatic cancer cell lines
that express GPRC5A mRNA) were plated on cover slips
at ∼50% confluency and fixed using 4% paraformaldehyde,
24 h after plating. Cells were stained with GPRC5A primary
antibody HPA007928 from Sigma Aldrich, United States, based
on protocols provided by the manufacturer, followed by 1 h
incubation with secondary goat-anti rabbit antibody (cat #
A-11008, Invitrogen, United States). Cells were also stained
with DAPI (4′,6-diamidino-2-phenylindole) to visualize nuclei.
Images were then taken via a Keyence BZ-X700 microscope and
analyzed using ImageJ (Schneider et al., 2012).
RESULTS
Limited information exists regarding the profile of GPCRs
expressed by malignant cells. Prior studies primarily assessed
individual GPCRs, in terms of expression, signaling and
functional activities (Lappano and Maggiolini, 2011; Feigin, 2013;
O’Hayre et al., 2014; Bar-Shavit et al., 2016; Liu et al., 2016;
Van Jaarsveld et al., 2016). TaqMan GPCR arrays provide an
unbiased method to identify and quantify non-chemosensory
GPCRs (other than those for taste, olfaction, and vision).
These arrays include ∼340 endoGPCRs (GPCRs that respond to
3http://bioinformatics.mdanderson.org/tcgambatch/
4https://nunofonseca.github.io/irap/
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FIGURE 1 | GPCR expression in B-CLL cells. (A) Venn diagram showing the number of GPCRs expressed in B-CLL cells (I1, I2, and I3) isolated from three different
patients with indolent CLL. I1, I2, and I3, expressed 142, 162, and 147 GPCRs, respectively, and shared in expression of 106 GPCRs. (B) G protein linkages of the
106 commonly expressed GPCRs. (C) The expression (1Ct normalized to 18S rRNA) and fold-increase in expression in indolent CLL cells compared to control B
cells of the four GPCRs (GABBR1, CNR2, CELSR1, and GPR92) with approximately twofold (or greater) increases in expression in the CLL cells. n = 3 biological
replicates of B-CLL, analyzed on one array each.
endogenously expressed hormones, neurotransmitters, autocoids
and metabolites),∼120 of which are orphan GPCRs (i.e., without
known physiologic agonists). Data for individual mRNAs as
a PCR Ct is compared to the Ct for a housekeeping gene
(e.g., 18S rRNA) to yield a1Ct value. Since Ct values are inversely
related to expression, lower Ct values indicate higher mRNA
expression.
Human B-CLL Cells and Control B Cells
B-cell Chronic Lymphocytic Leukemia, the most common adult
leukemia in economically developed countries, is characterized
by the accumulation of mature B cells, primarily as a consequence
of reduced apoptosis (Billard, 2014; Hallek, 2015). CLL is
clinically quite variable: patients with CLL can survive a few
months (aggressive CLL) or many years (indolent CLL) after
diagnosis (Nabhan and Rosen, 2014). Increases in cAMP can
promote apoptosis in CLL cells (Murray and Insel, 2013).
Analysis of malignant B cells from three patients with indolent
CLL identified 106 commonly detected (including 30 orphan)
GPCRs (Figure 1A). Most highly expressed GPCRs (1Ct < 18)
were expressed by all three patients. More of these GPCRs couple
to Gi than to other G proteins but 31 GPCRs have unknown G
protein linkages (Figure 1B). The highest expressed Gi-coupled
receptors include CXCR4, EBI2, and CCR7 (1Ct values of 12.2,
12.7, and 14.5, respectively). The highest expressed Gs-coupled
receptors include ADRB2 (β2-adrenergic receptor, 1Ct = 14.6)
and PTGER4 (1Ct = 14.9). Control B cells express 175 GPCRs,
including 101 of the 106 CLL-expressed GPCRs. B-CLL cells
have a greater than twofold increase in expression of a subset of
GPCRs that are highly expressed (1Ct ∼18 or less) in normal
B cells (Figure 1C): GABBR1 (GABA B1 receptor, 1Ct = 16),
CNR2 (CB2 cannabinoid receptor, 1Ct = 17 ), CELSR1 (an
orphan adhesion receptor, 1Ct = 17), and GPR92 (aka LPAR5,
a lysophosphatidic acid receptor,1Ct = 18).
Human Bone Marrow Stromal Natural
Killer Cells (BMNK Cells)
Bone marrow stromal natural killer cells, immortalized by
expression of human telomerase reverse transcriptase, enhance
the viability of primary cultures of B-CLL cells and are considered
an important component of the CLL microenvironment (Zhang
et al., 2012; ten Hacken and Burger, 2014). BMNK cells express
116 GPCRs, including 33 orphan GPCRs. The 20 highest
expressed GPCRs include seven orphan GPCRs [e.g., GPR176
(1Ct = 14.9), LPHN2 (1Ct = 15.5), CD97 (1Ct = 16.1)].
Gi-coupled GPCRs are the largest category of GPCRs for which
G protein linkage is known (Figure 2A). Such GPCRs include
a number of the highest expressed receptors, including F2R
FIGURE 2 | GPCR expression in BMNK cells. (A) G protein linkages of the 116 GPCRs detected in BMNK cells. (B) Venn diagram of GPCRs expressed in B-CLL
compared to BMNK cells, indicating that 51 GPCRs are shared but most receptors are unique for each cell-type. (C) Lower expression in the BMNK cells (higher
1Ct values) for most of the highest expressed GPCRs in B-CLL cells (lower 1Ct values). n = 1 for each cell type.
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TABLE 2 | GPCR expression in Triple-negative breast cancer cells: The 23
commonly detected GPCRs in four triple-negative breast cancer cell lines with
expression (1Ct) normalized to 18S rRNA.
Gene
name
1Ct vs 18S Gene
name
1Ct vs 18S Gene
name
1Ct vs 18S
FZD6 16.1 GPR126 17.7 P2RY11 18.4
CD97 16.6 GPRC5B 17.8 FZD1 18.4
GPR153 16.8 OXTR 17.9 BAI2 18.6
FZD4 16.9 LPHN2 18.0 GPR161 18.7
FZD2 17.2 FZD7 18.0 TBXA2R 19.4
F2R 17.4 GABBR1 18.0 MC1R 19.5
ADORA2B 17.5 GPR125 18.1 GPR135 20.7
OPN3 17.6 EDG3 18.3
(protease activated receptor 1, PAR1, 1Ct = 15.7), LPAR1 (also
known as EDG2;1Ct = 16.3), and SSTR1 (somatostatin receptor-
1,1Ct = 17.7). PAR1 and LPARs both couple to Gq and G12/13.
To determine the similarity in GPCR expression of CLL cells
and cells of their tumor microenvironment, we compared the
GPCR profiles of B-CLL and BMNK cells. Although 51 of the
106 shared GPCRs among B-CLL cells are also detected in BMNK
cells (Figure 2B), most of the highest expressed GPCRs in B-CLL
cells are either undetectable or expressed at much lower levels
in BMNK cells: 103 of the 106 commonly detected receptors
in B-CLL cells were more than twofold higher expressed than
in BMNK cells and almost all of the highly expressed GPCRs
in B-CLL cells have much lower expression in BMNK cells
(Figure 2C).
Human Breast Cancer Cells
We assessed GPCR expression in four human triple-negative
breast cancer cell lines (BT-20, HS-578, MDA-MB-157, and
MDA-MB-436) and a control cell line (MCF-10A, a breast
epithelial cell line). The four breast cancer cell lines expressed
on average 88 GPCRs and had shared expression of 23 GPCRs
(Table 2), 21 of which were also detected in the control cell line.
Gq-coupled GPCRs are more frequent among the GPCRs with
known G protein linkages (Figure 3A). Figure 3B shows the fold-
increases in expression for 11 of the commonly expressed GPCRs
with a greater than twofold increase in expression compared to
the control breast epithelial cell line. We detected two receptors
uniquely expressed in all breast cancer cell lines but not in control
cells: GPRC5B (a Class-C orphan receptor, 1Ct = 17.8) and
TBXA2R (thromboxane A2 receptor,1Ct = 19.4).
Table 2 shows the identities and average expression values
(1Ct normalized to 18S rRNA) of the 23 commonly expressed
GPCRs in the four breast cancer cell lines. Five of these receptors
(BAI2, GPR125, CD97, GPR126, and LPHN2) are members of the
adhesion family of GPCRs. Of note, GPR161, an orphan receptor
with more than twofold increase in expression, has previously
been reported to contribute to the malignant phenotype in triple-
negative breast cancer (Feigin et al., 2014).
Analysis of 47 invasive breast carcinomas, including triple-
negative cancer cell lines, in the Cancer Cell Line Encyclopedia
(CCLE, Barretina et al., 2012, hosted at the EBI expression
atlas, Kapushesky et al., 2009) revealed that the cell lines
express on average ∼107 GPCRs and highly express several
GPCRs identified in our studies above, including CD97, OXTR,
ADORA2B, and FZD7. As in the GPCR array studies, the cell
lines shared in the expression of relatively few GPCRs: only 19
(including CD97, MC1R, BAI2, FZD1, P2RY11, OPN3, GPR153,
and FZD4 in Table 2) were detected in all 47 cell lines. The
CCLE cell lines include 16 triple-negative cancers (including
four cell lines we assessed using GPCR arrays). Of the 23
commonly detected GPCRs in Table 2, 19 were detectable in all 16
CCLE triple-negative breast cancer cell lines; four other GPCRs
(LPHN2, GPRC5B, EDG3, TBXA2R) were detected in 11–14 of
the 16 cell lines. Hence, the GPCRs highlighted in Table 2 may
be ones that contribute to triple-negative breast cancer. Of note,
GPR161 is detected in all 16 triple-negative cell lines but only 24
of 31 cell lines from non-triple-negative cancers. With a higher
detection threshold (1 FPKM), GPR161 is detected in 12 of 16
triple-negative cell lines but only 13 of 31 other breast cancer cell
lines. On average, GPR161 is ∼1.6-fold higher expressed among
FIGURE 3 | GPCR expression in triple-negative breast cancer cells. (A) G protein linkages of the 23 commonly detected GPCRs in four breast cancer cell lines.
(B) Average (and SEM) of the fold-increases in expression of GPCRs in triple-negative breast cancer cells compared to control cells. Of the 23 commonly detected
GPCRs, the 11 shown have a greater than twofold average increase in expression. n = 4 cell lines, assayed on one array each.
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FIGURE 4 | GPCR expression in colon cancer cells. (A) Venn diagram
showing GPCRs expressed in two colon cancer cell lines, Caco-2 and T84
with 74 GPCRs commonly detected between the two cell lines. (B) G protein
linkage of the 74 commonly detected GPCRs. n = 2 cell lines, assayed on one
array each.
the triple negative cancer cell lines than in non-triple-negative cell
lines.
Human Colon Cancer Cell Lines
TaqMan array analysis of T-84 and Caco-2 colon adenocarcinoma
cell lines revealed that they share in expression of 74 GPCRs
(Figure 4A), including 24 Gi-, 23 Gq- and 11 Gs-coupled
receptors (Figure 4B). F2RL1 (PAR2, 1Ct = 15.3) is the
highest expressed Gq-coupled GPCR. Among the highest
expressed Gs-coupled GPCRs are adenosine A2B (ADORA2B,
1Ct = 17.6) and vasoactive intestinal peptide receptor 1 (VIPR1,
1Ct = 17.8). The highest expressed Gi-coupled receptors are
OXER1 (oxoeicosanoid receptor 1/GPR170, 1Ct = 17.3) and
EDG4/LPAR2 (lysophosphatidic acid receptor 2,1Ct = 17.3). Of
the 74 commonly detected receptors, 18 are orphans; GPR160 is
the highest expressed orphan GPCR.
Data mining of GPCR expression in 41 colon adenocarcinoma
cell lines in the CCLE (Kapushesky et al., 2009; Barretina et al.,
2012) yielded results consistent with those findings. On average,
the cell lines expressed 101 GPCRs of which 21 were commonly
expressed. F2R/PAR1 was the highest expressed Gi-coupled
GPCR (detected in all 41 cell lines). ADORA2B, the highest
expressed Gs-coupled GPCR, was detected in 39 cell lines. F2RL1
was the highest expressed Gq-coupled GPCR and overall, the
second highest expressed GPCR. Of note and relevant to data
for pancreatic cancer (see below), GPRC5A, an orphan receptor,
was the highest expressed GPCR, detected in 40 of 41 colon
adenocarcinoma cell lines and the highest expressed GPCR in 27
of the 41 cell lines.
Human Pancreatic Cancer Cells
Using TaqMan GPCR arrays, we assessed GPCR expression of
pancreatic cancer (PDAC) cell lines (AsPC-1 and MiaPaCa-
2), patient-derived primary PDAC cells (identified as 34E and
79E in Figure 5A), and a normal pancreatic ductal epithelial
(PDEC) cell line. We found that PDAC and PDEC cells express
∼100 GPCRs, of which 54 (including 20 orphan GPCRs)
were expressed in all four PDAC samples (Figure 5A). Those
shared GPCRs included most of the highly expressed GPCRs
in each cell line. Gi-coupled and Gq-coupled receptors are
the largest groups of GPCRs with known G protein linkages
(Figure 5B).
GPRC5A was the highest expressed GPCR of the 54 receptors
commonly expressed by the PDAC cells and had >10-fold
higher expression than any other GPCR. Compared to control
PDEC cells, GPRC5A had the greatest fold-increase (>eightfold)
in expression in all four PDAC cell samples with larger fold-
increases in the primary cancer cells, 34E and 79E (Figure 5C).
Human Pancreatic Cancer Tumor Tissue
TaqMan GPCR array analysis of three PDAC tumors revealed
that they share in expression of 77 GPCRs (Figure 6A),
16 of which are orphan receptors. The tumors expressed
∼150 or more GPCRs (i.e., more than did the PDAC cell
lines, Figures 5, 6), perhaps because of the heterogeneous
cell populations and their diverse GPCR repertoires in the
tumors. The G protein coupling of tumor-expressed GPCRs
was similar to that of PDAC cells (Cf. Figures 5B, 6B):
Gi- and Gq-coupled GPCRs were the largest categories of
receptors with known G protein coupling. Most of the highest
expressed GPCRs were commonly expressed among the tumor
samples.
As in the PDAC cells, GPRC5A was the highest expressed
GPCR in the tumor samples (∼fourfold more highly expressed
than any other GPCR). GPRC5A, an orphan GPCR, may couple
to Gi. (Hirano et al., 2006). Previous work suggested a role for
GPRC5A in various cancers (Zhou and Rigoutsos, 2014). Zhou
et al. (2016) have also noted high expression of GPRC5A in PDAC
and found that GPRC5A may contribute to cell proliferation,
survival, and drug-resistance in PDAC tumors.
Human Pancreatic Cancer-Associated
Fibroblasts (CAFs)
Cancer-associated fibroblasts, an abundant cell type in pancreatic
tumor microenvironment, contribute to the extensive fibrotic
stroma (desmoplasia) in PDAC. We sought to assess GPCR
expression in CAFs to investigate if (a) GPCRs may regulate
their pro-fibrotic phenotype and (b) GPCRs contribute to the
interaction between CAFs and PDAC cells.
We isolated CAFs from five PDAC patient tumors and
assessed GPCR expression in the CAFs by both RNA-seq and
Taqman GPCR arrays (Wiley et al., 2018), which allowed us
to compare results with the two methods. We also assessed
GPCR expression in normal PSCs, precursor cells for CAFs,
to determine if GPCR expression changes after PSCs convert
to CAFs.
Taqman GPCR arrays and RNA-seq detected ∼110 GPCRs
in CAFs and yielded similar results for identities of detected
GPCRs and fold-changes in expression between CAFs and PSCs
(Figure 7A and Wiley et al., 2018). The 82 GPCRs commonly
detected by Taqman arrays of five CAF samples (Figure 7B) link
to various Gα proteins (Figure 7C), most frequently to Gq/11 and
Gi/Go, and include 28 orphan GPCRs. F2R/PAR1 was the highest
expressed GPCR in CAFs, as also found in cardiac fibroblasts
(Snead and Insel, 2012). Multiple orphan and adhesion GPCRs
are highly expressed in CAFs. GPR68, a proton-sensing GPCR, is
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much higher expressed in CAFs than in PSCs and has functional
effects, including the production of IL6, which can promote the
growth of PDAC cells (Wiley et al., 2018).
Comparison of the repertoires of 82 GPCRs commonly
detected in CAFs and the 54 commonly detected GPCRs in PDAC
cells revealed 37 GPCRs that were detected in both cell types
(Figure 8A), among the highest expressed GPCRs in each cell
type (Figure 8B), and often expressed at comparable magnitudes
of expression. These commonly expressed GPCRs include certain
orphan GPCRs (e.g., GPRC5A, CD97, GPR126) and GPCRs that
are targets of approved drugs (e.g., OXTR, F2R/PAR1).
Expression of Novel GPCRs (GPRC5A
and GPR68) in PDAC Tumors and Cells
Analysis of differential gene expression in PDAC tumors (TCGA)
compared to normal pancreatic tissue (GTEx) revealed that
GPRC5A and GPR68 are more highly expressed in the tumors
than in normal tissue: GPRC5A is ∼50-fold increased in PDAC
compared to normal pancreatic tissue, and GPR68 has ∼10-fold
increased expression, each with a False Discovery Rate (FDR)
<< 0.05, indicating high statistical significance (Figure 9A). Both
GPCRs lack evidence for dependence on factors such as patient’s
sex and tumor grade (Figures 9B,C), suggesting that expression
FIGURE 5 | GPCR expression in pancreatic ductal adenocarcinoma (PDAC) cells. (A) Venn diagram showing GPCRs expressed in two PDAC cell lines (MiaPaCa,
AsPC-1) and primary PDAC cells (34E, 79E); 54 GPCRs were detected in all four samples. The number of GPCRs in each cell-line was: MiaPaCa-2: 92, AsPC-1:
114, 79E: 175, 34E: 130. (B) G protein linkage of the 54 commonly detected GPCRs. (C) Fold-increase in GPRC5A expression in PDAC cells compared to the
control pancreatic ductal epithelial cells (PDEC). n = 4 cell lines, each assayed on one array each.
FIGURE 6 | GPCR expression in pancreatic cancer tumors. (A) Venn diagram of GPCR expression, determined using Taqman GPCR arrays, of three PDAC tumor
samples with 77 GPCRs commonly detected among the samples. T1424, T1255, and T760 expressed 185, 175, and 145 GPCRs, respectively. (B) G-protein
linkage of the 77 commonly detected GPCRs. (C) GPRC5A is expressed at similar levels in PDAC cells and tumors. The highest expressed GPCRs in cancer cells
were also highly expressed in tumors. n = 3 primary tumors, each assayed on one array each.
FIGURE 7 | GPCR expression in CAFs. (A) Increase in expression, as determined by Taqman GPCR arrays or RNA-seq in one CAF sample (CAF3) compared to
pancreatic stellate cells (PSCs) of the 15 GPCRs with the largest increases in expression in CAFs compared to PSCs. (B) CAFs express ∼110 GPCRs, with 82
receptors commonly detected in five patient replicates tested. (C) G protein linkage of the 82 commonly detected GPCRs. Five separate CAF biological replicates
were analyzed via Taqman arrays, while three of these were also analyzed via RNA-seq.
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of these receptors increases early in tumor development and is
highly prevalent in both male and female PDAC patients.
Data in the CCLE database support these findings regarding
GPRC5A: it is the highest expressed GPCR in multiple PDAC
cell lines [EBI gene expression atlas (Kapushesky et al., 2009)
of results from cell lines in the CCLE (Barretina et al., 2012)].
GPRC5A is more highly expressed in every PDAC cell line with
31 of 33 PDAC cell lines having greater than twofold increased
expression. GPRC5A is the highest expressed GPCR in 21/33 cell
lines and among the three highest expressed GPCR in 30/33 cell
lines.
Immunocytochemistry staining of pancreatic cancer
cells supports the mRNA expression data, indicating the
presence of GPRC5A protein in these cells (Figure 10).
Other data document the expression of GPRC5A using
immunoblotting and immunohistochemistry in pancreatic
cancer cells and tumors, respectively (Uhlén et al., 2015;
Zhou et al., 2016, with relevant tumor staining data hosted at
proteinatlas.org/ENSG00000013588-GPRC5A/pathology). In
addition, other data show protein expression via
immunocytochemistry and immunoblotting, which confirm
the presence of GPR68 in pancreatic CAFs, and in PSCs in which
GPR68 is overexpressed via transfection (Wiley et al., 2018).
DISCUSSION
The results shown here are, we believe, the first use of an unbiased
(GPCRomic) approach to assess GPCR expression in the cells and
tumors we studied. qPCR-based TaqMan GPCR arrays provide a
means to identify and quantify GPCR mRNAs with a sensitivity
and specificity superior to commercial tiling arrays that assess
the entire transcriptome (Insel et al., 2015). Accordingly, gene
expression data from the latter type of arrays (including data
in public repositories) do not reveal an accurate or complete
assessment of the GPCR repertoire of cancer cells. Improved
detection by RNA-seq provides greater confidence regarding
GPCR expression than tiling arrays but expression of GPCRs as
a gene family has not previously been systematically culled out
of RNA-seq data on cancer. The results here show that data from
Taqman GPCR arrays and RNA-seq identify similar numbers of
GPCRs in breast and colon cancers cells and in PDAC tumors
and pancreatic CAFs. These assays hence provide complementary
means of detection of GPCR expression in cancer cells and
tumors.
A key conclusion from our studies is that each type of
cancer cell/tumor expresses a common set of GPCRs. Some cell
types and tumors express >150 different GPCRs, including ones
FIGURE 8 | Comparison of GPCR expression in PDAC cells and CAFs. (A) PDAC cells and CAFs share in expression of 37 GPCRs. (B) The 20 GPCRs shared in
expression by PDAC cells and CAFs and with the highest expression in PDAC cells and CAFs, determined by averaging GPCR expression in the two cell types.
Mean and SEM are indicated for 1Ct values (normalized to 18S rRNA). Lower 1 Ct values indicate higher expression.
FIGURE 9 | GPRC5A and GPR68 are highly expressed in PDAC tumors. (A) Median, upper and lower quartile expression values (indicated by the error bars) for
GPRC5A and GPR68 in PDAC tumors (TCGA, n = 147) and in normal pancreatic tissue (GTEx, n = 165). In PDAC tumors, GPRC5A is increased ∼50-fold (FDR
<< 0.05) and GPR68 is increased ∼10-fold (FDR << 0.05). (B) Mean (and SEM) expression of GPRC5A and GPR68 in PDAC tumors (in TCGA) with tumor grades
G1, G2, and G3. (C) Mean (and SEM) expression of GPRC5A and GPR68 in TCGA PDAC tumors from males and females. Expression differences for tumor grades
and between males and females are not statistically significant.
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FIGURE 10 | GPRC5A antibody staining in PDAC cells. (A) BXPC-3 (B) MIA
PaCa-2. Using RNA-seq and qPCR, MIA PaCa-2 cells express >10-fold more
GPRC5A mRNA than do BXPC-3 cells. Hence, MIA PaCa-2 cells stain more
intensely for GPRC5A. Magnification = 10×. Images are representative of data
for n = 3 separate slides for each cell line, respectively.
expressed at relatively high levels. Many of the highly expressed
receptors are orphan GPCRs. As we show for CLL and PDAC
cells, multiple GPCRs are much more highly expressed by the
malignant cells than by their normal precursors, B cells, and
PDEC cells, respectively.
Certain cancer cell types may possess a “GPCR signature,”
such that one or more GPCRs might serve as novel biomarkers
and/or as therapeutic targets for such cancers. Therapeutic utility
will require validation of the GPCRs preferentially expressed
in cancer cells, including confirmation of expression of GPCR
proteins, their signaling, and functional roles. Initial efforts
indicate that at least certain of the GPCRs we have identified
are functional in cancer cells [e.g., GPR161 in breast cancer
(Feigin et al., 2014) and GPRC5A in pancreatic cancer (Zhou
et al., 2016)] and in the microenvironment (e.g., GPR68; Wiley
et al., 2018). These examples suggest that certain GPCRs are
selectively overexpressed in specific cancer types, suggesting that
different types of cancer may each possess a unique “GPCR-
ome.” Certain GPCRs (e.g., CD97 and GPR56) are expressed in
multiple cancer types, but also are widely expressed in normal
tissue and cells (e.g., Uhlén et al., 2015, corresponding data for
each GPCR hosted at proteinatlas.org). Besides the presence of
these “promiscuously” expressed receptors, there does not appear
to be a GPCR signature in common among cancer cells from
different types of cancer.
In addition to cancer cells themselves, cells in the tumor
microenvironment, as we show for BMNK cells and pancreatic
CAFs, express a large number of GPCRs. Certain GPCRs, such
as chemokine receptors, have been implicated in intercellular
communication that can facilitate cancer cell proliferation,
protection from apoptosis, and other features of the malignant
phenotype (Hanahan and Weinberg, 2011; Vela et al., 2015; Guo
et al., 2016). In addition, we recently documented a functional
role for CAF-expressed GPR68 and its interaction with PDAC
cells (Wiley et al., 2018).
Assessment of data in public databases has certain caveats,
especially as related to reliability, reproducibility, and consistency
of results from different labs, which may use different procedures
and bioinformatics tools. We find that data derived from qPCR
based arrays yield conclusions broadly supportive of those from
analysis of public databases: Taqman array data for GPCR
expression in PDAC tumors and cells that show GPRC5A is
highly expressed are supported by TCGA data for PDAC tumors
and RNAseq data from various cell lines (from the EBI portal).
These complementary data suggest that while sources of technical
variability may exist between datasets, the overall patterns of
GPCR expression observed, and conclusions derived therefrom,
are robust and reproducible.
As noted above, GPCRs with increased expression in cancer
cells may be novel therapeutic targets. These include GPCRs
for which approved drugs exist while other receptors identified
include orphan, frizzled and/or adhesion GPCRs, which may
provide unique therapeutic opportunities. GPCRs are commonly
targeted by small molecules but other approaches may be
possible, for example, techniques to blunt GPCR expression,
GPCR-directed antibodies, antibody-drug conjugates, and bio-
conjugates. (Junttila et al., 2015; Lelle et al., 2015; Gong et al.,
2016; Gilabert-Oriol et al., 2017).
The approach described here – studies of patient-derived
cells and cell lines to define a GPCR profile and the differential
expression of GPCRs of cancer cells compared to that of normal
cell precursors—should be applicable to other types of cancer.
Perhaps therapies directed at such GPCRs can be part of
therapeutic cocktails with multiple agents, especially since drug
combinations may be able to optimize efficacy and minimize side-
effects and drug resistance in cancer therapy (Atkins and Larkin,
2016; Alsaab et al., 2017; Corraliza-Gorjón et al., 2017; Gotwals
et al., 2017; Lopez and Banerji, 2017).
AUTHOR CONTRIBUTIONS
PI, KS, HY, RC, SW, MF, and FM designed the experiments. AW,
TK, TM, HY, LZ, SW, DL, and FM conducted experiments with
GPCR arrays and analyzed data. AL and RF isolated and initially
cultured pancreatic CAFs, PDAC, and PDEC cells and provided
PDAC tumor samples. MF provided cDNA from breast cancer
cell lines. KS performed immunocytochemistry, compiled and
analyzed array data and mined data from databases. PI, KS, RC,
and FM wrote the manuscript. All authors read and approved the
manuscript.
FUNDING
Financial support for these studies was provided by Roche, the
Lymphoma and Leukemia Society, Friends of ANCHOR, an
ASPET-Astellas Award and grants from the National Institutes
of Health, National Cancer Institute (CA189477, CA121938,
and CA155620); National Cancer Institute (NCI) Therapeutic
Training Grant No. 5T32CA121938, NIH/NCI Research Grants
R21 CA189477, an ASPET David Lehr Award, and the Padres
Pedal the Cause #PTC2017 award.
ACKNOWLEDGMENTS
We dedicate this article to our colleague Nakon Aroonsakool,
who assisted with some of the studies reported here. His untimely
death in April, 2016 deeply saddened all of the members of the
Frontiers in Pharmacology | www.frontiersin.org 9 May 2018 | Volume 9 | Article 431
fphar-09-00431 May 17, 2018 Time: 16:38 # 10
Insel et al. GPCRomics in Cancer
Insel laboratory. We thank Thomas Kipps and Laura Rassenti
(UCSD Moores Cancer Center) for their assistance in obtaining
samples from patients with CLL and the BMNK cells and Pinyi
Du and the UCSD Center for AIDS Research (CFAR) Genomics
Core for the assistance in conducting TaqMan GPCR array
studies.
REFERENCES
Alexander, S. P., Kelly, E., Marrion, N. V., Peters, J. A., Faccenda, E.,
Harding, S. D., et al. (2017). The Concise Guide to PHARMACOLOGY
2017/18: Overview. Br. J. Pharmacol. 174(Suppl. 1), S1–S16. doi: 10.1111/bph.
13882
Alsaab, H. O., Sau, S., Alzhrani, R., Tatiparti, K., Bhise, K., Kashaw, S. K.,
et al. (2017). PD-1 and PD-L1 checkpoint signaling inhibition for cancer
immunotherapy: mechanism, combinations, and clinical outcome. Front.
Pharmacol. 8:561. doi: 10.3389/fphar.2017.00561
Amisten, S., Neville, M., Hawkes, R., Persaud, S. J., Karpe, F., and Salehi, A.
(2015). An atlas of G-protein coupled receptor expression and function in
human subcutaneous adipose tissue. Pharmacol. Ther. 146, 61–93. doi: 10.1016/
j.pharmthera.2014.09.007
Atkins, M. B., and Larkin, J. (2016). Immunotherapy combined or sequenced with
targeted therapy in the treatment of solid tumors: current perspectives. J. Natl.
Cancer Inst. 108:djv414. doi: 10.1093/jnci/djv414
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S.,
et al. (2012). The Cancer Cell Line Encyclopedia enables predictive modelling
of anticancer drug sensitivity. Nature 483, 603–607. doi: 10.1038/nature11003
Bar-Shavit, R., Maoz, M., Kancharla, A., Nag, J. K., Agranovich, D., Grisaru-
Granovsky, S., et al. (2016). G protein-coupled receptors in cancer. Int. J. Mol.
Sci. 17:E1320. doi: 10.3390/ijms17081320
Billard, C. (2014). Apoptosis inducers in chronic lymphocytic leukemia. Oncotarget
5, 309–325. doi: 10.18632/oncotarget.1480
Borad, M. J., and LoRusso, P. M. (2017). Twenty-first century precision medicine
in oncology: genomic profiling in patients with cancer. Mayo Clin. Proc. 92,
1583–1591. doi: 10.1016/j.mayocp.2017.08.002
Chae, Y. K., Pan, A. P., Davis, A. A., Patel, S. P., Carneiro, B. A., Kurzrock, R.,
et al. (2017). Path toward precision oncology: review of targeted therapy studies
and tools to aid in defining “Actionability” of a molecular lesion and patient
management support. Mol. Cancer Ther. 16, 2645–2655. doi: 10.1158/1535-
7163.MCT-17-0597
Chettoor, A. M., Givan, S. A., Cole, R. A., Coker, C. T., Unger-Wallace, E.,
Vejlupkova, Z., et al. (2014). Discovery of novel transcripts and gametophytic
functions via RNA-seq analysis of maize gametophytic transcriptomes. Genome
Biol. 15:414. doi: 10.1186/s13059-014-0414-2
Cogdill, A. P., Andrews, M. C., and Wargo, J. A. (2017). Hallmarks of response to
immune checkpoint blockade. Br. J. Cancer 117, 1–7. doi: 10.1038/bjc.2017.136
Consortium, G. T. E. X. (2013). The genotype-tissue expression (GTEx) project.
Nat. Genet. 45, 580–585. doi: 10.1038/ng.2653
Corraliza-Gorjón, I., Somovilla-Crespo, B., Santamaria, S., Garcia-Sanz, J. A., and
Kremer, L. (2017). New strategies using antibody combinations to increase
cancer treatment effectiveness. Front. Immunol. 8:1804. doi: 10.3389/fimmu.
2017.01804
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., et al.
(2013). STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21.
doi: 10.1093/bioinformatics/bts635
Dorsam, R. T., and Gutkind, J. S. (2007). G-protein-coupled receptors and cancer.
Nat. Rev. Cancer 7, 79–94. doi: 10.1038/nrc2069
Feigin, M. E. (2013). Harnessing the genome for characterization of G-protein
coupled receptors in cancer pathogenesis. FEBS J. 280, 4729–4738. doi: 10.1111/
febs.12473
Feigin, M. E., Xue, B., Hammell, M. C., and Muthuswamy, S. K. (2014). G-protein–
coupled receptor GPR161 is overexpressed in breast cancer and is a promoter
of cell proliferation and invasion. Proc. Natl. Acad. Sci. U.S.A. 111, 4191–4196.
doi: 10.1073/pnas.1320239111
Fonseca, N. A., Marioni, J., and Brazma, A. (2014). RNA-seq gene profiling-a
systematic empirical comparison. PLoS One 9:e107026. doi: 10.1371/journal.
pone.0107026
Gilabert-Oriol, R., Furness, S. G., Stringer, B. W., Weng, A., Fuchs, H., Day,
B. W., et al. (2017). Dianthin-30 or gelonin versus monomethyl auristatin E,
each configured with an anti-calcitonin receptor antibody, are differentially
potent in vitro in high-grade glioma cell lines derived from glioblastoma.
Cancer Immunol. Immunother. 66, 1217–1228. doi: 10.1007/s00262-017-
2013-z
Gong, X., Azhdarinia, A., Ghosh, S. C., Xiong, W., An, Z., Liu, Q., et al. (2016).
LGR5-targeted antibody–drug conjugate eradicates gastrointestinal tumors and
prevents recurrence. Mol. Cancer Ther. 15, 1580–1590. doi: 10.1158/1535-7163.
MCT-16-0114
Gotwals, P., Cameron, S., Cipolletta, D., Cremasco, V., Crystal, A., Hewes, B., et al.
(2017). Prospects for combining targeted and conventional cancer therapy with
immunotherapy. Nat. Rev. Cancer 17, 286–301. doi: 10.1038/nrc.2017.17
Guo, F., Wang, Y., Liu, J., Mok, S. C., Xue, F., and Zhang, W. (2016).
CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal
neighbors in oncogenic communication networks. Oncogene 35, 816–826.
doi: 10.1038/onc.2015.139
Hallek, M. (2015). Chronic lymphocytic leukemia: 2015 update on diagnosis, risk
stratification, and treatment. Am. J. Hematol. 90, 446–460. doi: 10.1002/ajh.
23979
Hanahan, D., and Weinberg, R. A. (2011). Hallmarks of cancer: the next generation.
Cell 144, 646–674. doi: 10.1016/j.cell.2011.02.013
Hirano, M., Zang, L., Oka, T., Ito, Y., Shimada, Y., Nishimura, Y., et al. (2006).
Novel reciprocal regulation of cAMP signaling and apoptosis by orphan
G-protein-coupled receptor GPRC5A gene expression. Biochem. Biophys. Res.
Commun. 351, 185–191. doi: 10.1016/j.bbrc.2006.10.016
Hyman, D. M., Taylor, B. S., and Baselga, J. (2017). Implementing genome-driven
oncology. Cell 168, 584–599. doi: 10.1016/j.cell.2016.12.015
Insel, P. A., Wilderman, A., Zambon, A. C., Snead, A. N., Murray, F.,
Aroonsakool, N., et al. (2015). G protein–coupled receptor (GPCR)
expression in native cells:“novel” endoGPCRs as physiologic regulators and
therapeutic targets. Mol. Pharmacol. 88, 181–187. doi: 10.1124/mol.115.
098129
Insel, P. A., Wilderman, A., Zhang, L., Keshwani, M. M., and Zambon, A. C.
(2014). Cyclic AMP/PKA-promoted apoptosis: insights from studies of S49
lymphoma cells. Horm. Metab. Res. 46, 854–862. doi: 10.1055/s-0034-13
84519
Insel, P. A., Zhang, L., Murray, F., Yokouchi, H., and Zambon, A. C. (2012).
Cyclic AMP is both a pro-apoptotic and anti-apoptotic second messenger. Acta
Physiol. 204, 277–287. doi: 10.1111/j.1748-1716.2011.02273.x
Jung, G., Fajardo, G., Ribeiro, A. J., Kooiker, K. B., Coronado, M., Zhao, M., et al.
(2016). Time-dependent evolution of functional vs. remodeling signaling in
induced pluripotent stem cell-derived cardiomyocytes and induced maturation
with biomechanical stimulation. FASEB J. 30, 1464–1479. doi: 10.1096/fj.15-
280982
Junttila, M. R., Mao, W., Wang, X., Wang, B. E., Pham, T., Flygare, J., et al. (2015).
Targeting LGR5+ cells with an antibody-drug conjugate for the treatment
of colon cancer. Sci. Transl. Med. 7:314ra186. doi: 10.1126/scitranslmed.aac
7433
Kapushesky, M., Emam, I., Holloway, E., Kurnosov, P., Zorin, A., Malone, J., et al.
(2009). Gene expression atlas at the European bioinformatics institute. Nucleic
Acids Res. 38(Suppl._1), D690–D698.
Lappano, R., and Maggiolini, M. (2011). G protein-coupled receptors: novel targets
for drug discovery in cancer. Nat. Rev. Drug Discov. 10, 47–60. doi: 10.1038/
nrd3320
Lelle, M., Kaloyanova, S., Freidel, C., Theodoropoulou, M., Musheev, M.,
Niehrs, C., et al. (2015). Octreotide-mediated tumor-targeted drug delivery
via a cleavable doxorubicin–peptide conjugate. Mol. Pharm. 12, 4290–4300.
doi: 10.1021/acs.molpharmaceut.5b00487
Li, B., and Dewey, C. N. (2011). RSEM: accurate transcript quantification from
RNA-Seq data with or without a reference genome. BMC Bioinformatics 12:323.
doi: 10.1186/1471-2105-12-323
Lim, W. A., and June, C. H. (2017). The principles of engineering immune cells to
treat cancer. Cell 168, 724–740. doi: 10.1016/j.cell.2017.01.016
Frontiers in Pharmacology | www.frontiersin.org 10 May 2018 | Volume 9 | Article 431
fphar-09-00431 May 17, 2018 Time: 16:38 # 11
Insel et al. GPCRomics in Cancer
Liu, Y., An, S., Ward, R., Yang, Y., Guo, X. X., Li, W., et al. (2016). G protein-
coupled receptors as promising cancer targets. Cancer Lett. 376, 226–239.
doi: 10.1016/j.canlet.2016.03.031
Lopez, J. S., and Banerji, U. (2017). Combine and conquer: challenges for targeted
therapy combinations in early phase trials. Nat. Rev. Clin. Oncol. 14, 57–66.
doi: 10.1038/nrclinonc.2016.96
Murray, F., and Insel, P. A. (2013). Targeting cAMP in chronic lymphocytic
leukemia: a pathway-dependent approach for the treatment of leukemia and
lymphoma. Expert Opin. Ther. Targets 17, 937–949. doi: 10.1517/14728222.
2013.798304
Nabhan, C., and Rosen, S. T. (2014). Chronic lymphocytic leukemia:
a clinical review. JAMA 312, 2265–2276. doi: 10.1001/jama.2014.
14553
O’Hayre, M., Degese, M. S., and Gutkind, J. S. (2014). Novel insights into G protein
and G protein-coupled receptor signaling in cancer. Curr. Opin. Cell Biol. 27,
126–135. doi: 10.1016/j.ceb.2014.01.005
Robinson, M. D., McCarthy, D. J., and Smyth, G. K. (2010). edgeR: a
Bioconductor package for differential expression analysis of digital gene
expression data. Bioinformatics 26, 139–140. doi: 10.1093/bioinformatics/
btp616
Schneider, C. A., Rasband, W. S., and Eliceiri, K. W. (2012). NIH Image to ImageJ:
25 years of image analysis. Nat. Methods 9, 671–675. doi: 10.1038/nmeth.
2089
Schwaederle, M., Zhao, M., Lee, J. J., Eggermont, A. M., Schilsky, R. L.,
Mendelsohn, J., et al. (2015). Impact of precision medicine in diverse cancers:
a meta-analysis of phase II clinical trials. J. Clin. Oncol. 33, 3817–3825.
doi: 10.1200/JCO.2015.61.5997
Smyth, G. K. (2005). “Limma: linear models for microarray data,” in Bioinformatics
and Computational Biology Solutions Using R and Bioconductor. Statistics for
Biology and Health, eds R. Gentleman, V. J. Carey, W. Huber, R. A. Irizarry, and
S. Dudoit (New York, NY: Springer), 397–420. doi: 10.1007/0-387-29362-0_23
Snead, A. N., and Insel, P. A. (2012). Defining the cellular repertoire of
GPCRs identifies a profibrotic role for the most highly expressed receptor,
protease-activated receptor 1, in cardiac fibroblasts. FASEB J. 26, 4540–4547.
doi: 10.1096/fj.12-213496
Sriram, K., and Insel, P. A. (2018). GPCRs as targets for approved drugs: How many
targets and how many drugs? Mol. Pharmacol. 93, 251–258
ten Hacken, E., and Burger, J. A. (2014). Microenvironment dependency
in chronic lymphocytic leukemia: the basis for new targeted therapies.
Pharmacol. Ther. 144, 338–348. doi: 10.1016/j.pharmthera.2014.
07.003
Trapnell, C., Roberts, A., Goff, L., Pertea, G., Kim, D., Kelley, D. R., et al. (2012).
Differential gene and transcript expression analysis of RNA-seq experiments
with TopHat and Cuﬄinks. Nat. Protoc. 7, 562–578. doi: 10.1038/nprot.
2012.016
Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P.,
Mardinoglu, A., et al. (2015). Tissue-based map of the human proteome. Science
347:1260419. doi: 10.1126/science.1260419
Van Jaarsveld, M. T. M., Houthuijzen, J. M., and Voest, E. E. (2016). Molecular
mechanisms of target recognition by lipid GPCRs: relevance for cancer.
Oncogene 35, 4021–4035. doi: 10.1038/onc.2015.467
Vela, M., Aris, M., Llorente, M., Garcia-Sanz, J. A., and Kremer, L.
(2015). Chemokine receptor-specific antibodies in cancer immunotherapy:
achievements and challenges. Front. Immunol. 6:12. doi: 10.3389/fimmu.2015.
00012
Vivian, J., Rao, A. A., Nothaft, F. A., Ketchum, C., Armstrong, J., Novak, A., et al.
(2017). Toil enables reproducible, open source, big biomedical data analyses.
Nat. Biotechnol. 35, 314–316. doi: 10.1038/nbt.3772
Walker, C. S., Eftekhari, S., Bower, R. L., Wilderman, A., Insel, P. A., Edvinsson, L.,
et al. (2015). A second trigeminal CGRP receptor: function and expression
of the AMY1 receptor. Ann. Clin. Transl. Neurol. 2, 595–608. doi: 10.1002/
acn3.197
Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R. M., Ozenberger, B. A.,
Ellrott, K., et al. (2013). The cancer genome atlas pan-cancer analysis project.
Nat. Genet. 45, 1113–1120. doi: 10.1038/ng.2764
Wiley, S. Z., Sriram, K., Liang, W., Chang, S. E., French, R., McCann, T.,
et al. (2018). GPR68, a proton-sensing GPCR, mediates interaction of cancer-
associated fibroblasts and cancer cells. FASEB J. 32, 1170–1183. doi: 10.1096/fj.
201700834R
Zhang, W., Trachootham, D., Liu, J., Chen, G., Pelicano, H., Garcia-Prieto, C., et al.
(2012). Stromal control of cystine metabolism promotes cancer cell survival
in chronic lymphocytic leukaemia. Nat. Cell Biol. 14, 276–286. doi: 10.1038/
ncb2432
Zhang, Y., Chen, K., Sloan, S. A., Bennett, M. L., Scholze, A. R., O’Keeffe, S.,
et al. (2014). An RNA-sequencing transcriptome and splicing database of glia,
neurons, and vascular cells of the cerebral cortex. J. Neurosci. 34, 11929–11947.
doi: 10.1523/JNEUROSCI.1860-14.2014
Zhou, H., and Rigoutsos, I. (2014). The emerging roles of GPRC5A in diseases.
Oncoscience 1, 765–776. doi: 10.18632/oncoscience.104
Zhou, H., Telonis, A. G., Jing, Y., Xia, N. L., Biederman, L., Jimbo, M., et al. (2016).
GPRC5A is a potential oncogene in pancreatic ductal adenocarcinoma cells that
is upregulated by gemcitabine with help from HuR. Cell Death Dis. 7:e2294.
doi: 10.1038/cddis.2016.169
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2018 Insel, Sriram, Wiley, Wilderman, Katakia, McCann, Yokouchi,
Zhang, Corriden, Liu, Feigin, French, Lowy and Murray. This is an open-access
article distributed under the terms of the Creative Commons Attribution License
(CC BY). The use, distribution or reproduction in other forums is permitted, provided
the original author(s) and the copyright owner are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Pharmacology | www.frontiersin.org 11 May 2018 | Volume 9 | Article 431
